UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

 

 

 

SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

ALBIREO PHARMA, INC.

(Name of Subject Company)

 

 

 

ALBIREO PHARMA, INC.

(Name of Person Filing Statement)

 

 

 

Common Stock, $0.01 par value per share

(Title of Class of Securities)

 

01345P106
(CUSIP Number of Class of Securities)

 

Jason G. Duncan
Chief Legal Officer, General Counsel and Secretary
Albireo Pharma, Inc.
53 State Street, 19th Floor
Boston, Massachusetts, 02109
(857) 254-5555

 

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)

 

With copies to:

 

Krishna Veeraraghavan
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, NY 10019-6064
(212) 373-3000

 

 

 

x       Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

 

 

 

·Employee Presentation (Exhibit 99.1)

 

 

 

Albireo Pharma (NASDAQ:ALBO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Albireo Pharma.